Immunophenotyping · Receptor occupancy · Immune monitoring
Multiplex flow cytometry on the Beckman Coulter CytoFLEX S — four lasers (405, 488, 638, and 808 nm) and up to 13 biomarkers per tube.
Cell profiling
Immunophenotyping identifies the cell populations in a heterogeneous sample and measures their proportions, using one or more labeled antibodies against unique immunological markers.
Many of these are CD (cluster of differentiation) markers, commonly used to detect specific immune cell populations and subpopulations.
B lymphocytes
CD19, CD20, or CD30
T lymphocytes
CD4 and CD8
Natural killer cells
CD161 and CD56 or CD16
Myeloid cells
CD13, CD14, CD33
Immature precursors
CD34, CD38, or CD59
Reticulocytes
CD71
Pharmacodynamic biomarkers
Receptor occupancy (RO) assays quantify how antibody-based therapeutics bind their cell-surface targets. They generate pharmacodynamic (PD) data that can be paired with pharmacokinetic (PK) profiles to model PK/PD relationships in nonclinical and clinical studies.
Measures unbound receptors using a labeled antibody that competes with the therapeutic for the same binding site — critical for assessing cell specificity and therapeutic dose.
Measures total receptor expression with a non-competing antibody that binds a different site on the receptor, revealing receptor internalization after therapeutic binding.
Tell us about your therapeutic and target. We will design the RO format that fits.
More flow cytometry
Flow assays validated to the level your study requires, including GLP and CLIA, in line with CLSI H62 guidance for assays performed by flow cytometry.
Isolation of B cells, T cells, regulatory T cells, and rare cells.
Immune monitoring for preclinical and clinical studies under GxP or CLIA.
Testing is performed at PacificDx, our CLIA-certified, CAP-accredited laboratory, for preclinical and clinical studies.